# Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

> **NCT00801385** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 47 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** sorafenib tosylate
- **GENETIC:** DNA analysis
- **GENETIC:** mutation analysis
- **GENETIC:** polymerase chain reaction
- **GENETIC:** protein analysis
- **GENETIC:** protein expression analysis
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00801385
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-09
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2009-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801385, "Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00801385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*